Marksans Pharma Limited
Symbol: MARKSANS.NS
NSE
158.25
INRDzisiejsza cena rynkowa
22.7836
Wskaźnik P/E
0.5408
Wskaźnik PEG
71.71B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Marksans Pharma Limited (MARKSANS-NS) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 27678.4 | 7191.6 | 3466.9 | 2093.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 34038.7 | 3367.2 | 4.3 | 17.2 | |||||||||||||||||||
balance-sheet.row.net-receivables | 8696.08 | 4187.6 | 4115.6 | 2767.3 | |||||||||||||||||||
balance-sheet.row.inventory | 10153.42 | 4847.4 | 4244.4 | 4043.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 1029.74 | 526.4 | 185.1 | 118.2 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 47557.64 | 16753 | 12012 | 9022.5 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8581.34 | 3868.9 | 3422.9 | 2540.2 | |||||||||||||||||||
balance-sheet.row.goodwill | 771.91 | 384.9 | 300.3 | 195.9 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 1395.4 | 708 | 585.7 | 474.4 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 2167.31 | 1092.9 | 885.9 | 670.2 | |||||||||||||||||||
balance-sheet.row.long-term-investments | -6433 | -3332.4 | -62 | 8.4 | |||||||||||||||||||
balance-sheet.row.tax-assets | 6517.3 | 3375.9 | 38.6 | 8 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | -13350.95 | 145.7 | 103.7 | 33.2 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | -2518 | 5150.9 | 4389 | 3260 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 45039.64 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.account-payables | 4309.35 | 2306 | 2000.8 | 1686.6 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 1073.1 | 572.6 | 693.4 | 247.8 | |||||||||||||||||||
balance-sheet.row.tax-payables | 667.33 | 252.8 | 173.3 | 300.2 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 1267.38 | 656.9 | 414.3 | 93.3 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 121.1 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 321.13 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 376.6 | 112.4 | 543 | 639.3 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1681.51 | 843.3 | 609.1 | 245 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1572.51 | 813.6 | 694.9 | 153.6 | |||||||||||||||||||
balance-sheet.row.total-liab | 8418.8 | 4253.2 | 4171.3 | 3229 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 13274.17 | 13274.2 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.common-stock | 906.32 | 453.2 | 409.3 | 409.3 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 10913.4 | 10913.4 | 5093.1 | 3349.3 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 58687.73 | 4177.4 | 4788.4 | 3355 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | -10953.25 | -11366.6 | 1731.9 | 1751.3 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 72828.37 | 17451.6 | 12022.7 | 8864.9 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 81660.48 | 21903.9 | 16401 | 12282.5 | |||||||||||||||||||
balance-sheet.row.minority-interest | 413.31 | 199.1 | 207 | 188.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 73241.68 | 17650.7 | 12229.7 | 9053.5 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 81660.48 | - | - | - | |||||||||||||||||||
Total Investments | 27605.7 | 34.8 | 26.1 | 25.6 | |||||||||||||||||||
balance-sheet.row.total-debt | 2340.48 | 1229.5 | 1107.8 | 341 | |||||||||||||||||||
balance-sheet.row.net-debt | 8700.78 | -2594.9 | -2354.8 | -1752.8 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 3181.21 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1114.7 | -1107 | -1500.3 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | -275.2 | -1039.3 | -367.4 | |||||||||||||||||
cash-flows.row.inventory | 0 | -448.5 | -178.5 | -1624.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 224.2 | 184.9 | 417.8 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -615.2 | -74.1 | 74.1 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -3181.21 | -406.3 | -823.3 | -95.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1343.16 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -266.1 | 0.3 | 5.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -1897.7 | -1.5 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2163.8 | -0.3 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -2055.8 | 47.9 | 10.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -2592.1 | -416.9 | -449 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2295.4 | -225.5 | -1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2747.1 | 911.5 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -451.7 | -225.5 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -101.7 | -105.8 | -40.9 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 2080 | 440.4 | -110.9 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 1978.3 | 795.1 | -152.9 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -1428.6 | -1 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 1343.16 | 1760.3 | 1370.8 | 1185.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 21580.94 | 3824.4 | 3492.7 | 2122.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 20237.78 | 2064.1 | 2121.8 | 937.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 1343.16 | 2374.1 | 992.6 | 1787.4 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -536.3 | -463.3 | -464.2 | |||||||||||||||||
cash-flows.row.free-cash-flow | 1343.16 | 1837.8 | 529.3 | 1323.2 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 21033.72 | 18521.4 | 14801.2 | 13683.7 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 10121.39 | 9213.6 | 7480.2 | 6186 | |||||||||||||||||||
income-statement-row.row.gross-profit | 10912.33 | 9307.8 | 7321.1 | 7497.8 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 283.89 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 6999.05 | 6433.1 | 5153.7 | 4310.6 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 17120.44 | 15646.7 | 12633.9 | 10496.6 | |||||||||||||||||||
income-statement-row.row.interest-income | 158.31 | 59.4 | 59.7 | 11.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 449.01 | 593.1 | 95.6 | 38.7 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 12.93 | 499.2 | 334.1 | -70.6 | |||||||||||||||||||
income-statement-row.row.interest-expense | 88.03 | 91.3 | 53.9 | 34.7 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 671.58 | 518.5 | 447.8 | 361.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 5033.87 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 4261.33 | 2877.3 | 2141 | 3092.2 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 4274.26 | 3376.5 | 2475.1 | 3021.6 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 1074.63 | 723.3 | 607 | 636.3 | |||||||||||||||||||
income-statement-row.row.net-income | 3173.43 | 2663.1 | 1845.7 | 2385.4 |
Często zadawane pytania
Ile wynosi Marksans Pharma Limited (MARKSANS.NS) aktywów ogółem?
Marksans Pharma Limited (MARKSANS.NS) całkowite aktywa to 21903890000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 11173630000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.519.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 2.964.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.151.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.203.
Co to jest Marksans Pharma Limited (MARKSANS.NS) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 2663080000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 1229450000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 6433130000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to -6611350000.000.